Large Intestine Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRG016 MIFTS: 38	Large Intestine Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Large Intestine Adenocarcinoma

MalaCards integrated aliases for Large Intestine Adenocarcinoma:

Name: Large Intestine Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Large Intestine ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050913

UMLS ⁷³ C1319315

Sources

Summaries for Large Intestine Adenocarcinoma

Disease Ontology : ¹² A large intestine cancer that has material basis in epithelial cells of glandular origin.

MalaCards based summary : Large Intestine Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to cystic basal cell carcinoma and vaginal benign neoplasm. An important gene associated with Large Intestine Adenocarcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Reduced mammosphere formation and cellular

Sources

Related Diseases for Large Intestine Adenocarcinoma

Diseases related to Large Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)

#	Related Disease	Score	Top Affiliating Genes
1	cystic basal cell carcinoma	10.7	KRT20 KRT7
2	vaginal benign neoplasm	10.7	KRT20 KRT7
3	seminal vesicle adenocarcinoma	10.7	KRT20 KRT7
4	transverse colon cancer	10.7	KRT20 KRT7
5	appendix adenocarcinoma	10.7	KRT20 KRT7
6	ovarian large-cell neuroendocrine carcinoma	10.7	KRT20 KRT7
7	vaginal adenoma	10.7	KRT20 KRT7
8	vaginal tubulovillous adenoma	10.7	KRT20 KRT7
9	eyelid neoplasm	10.7	KRT20 KRT7
10	glandular cystitis	10.7	KRT20 KRT7
11	malignant syringoma	10.7	KRT20 KRT7
12	krukenberg carcinoma	10.7	KRT20 KRT7
13	small cell carcinoma of the bladder	10.7	KRT20 KRT7
14	eccrine sweat gland neoplasm	10.7	KRT20 KRT7
15	mucinous bronchioloalveolar adenocarcinoma	10.7	KRT20 KRT7
16	bile duct cystadenocarcinoma	10.7	KRT20 KRT7
17	intratubular embryonal carcinoma	10.7	KRT20 KRT7
18	ovarian mucinous adenocarcinoma	10.7	KRT20 KRT7
19	thymus adenocarcinoma	10.7	KRT20 KRT7
20	meibomian cyst	10.7	KRT20 KRT7
21	bladder lymphoma	10.7	KRT20 KRT7
22	papillary serous adenocarcinoma	10.7	KRT20 KRT7
23	jejunal adenocarcinoma	10.7	KRT20 KRT7
24	chronic cystitis	10.7	KRT20 KRT7
25	medulloepithelioma	10.7	KRT20 KRT7
26	glycogen-rich clear cell breast carcinoma	10.7	KRT20 KRT7
27	rectum adenocarcinoma	10.6	KRT20 KRT7
28	renal pelvis carcinoma	10.6	KRT20 KRT7
29	ampulla of vater neoplasm	10.6	KRT20 KRT7
30	appendix cancer	10.6	KRT20 KRT7
31	ampulla of vater adenocarcinoma	10.6	KRT20 KRT7
32	mucinous cystadenocarcinoma	10.6	KRT20 KRT7
33	biliary papillomatosis	10.6	KRT20 KRT7
34	endocervical adenocarcinoma	10.6	KRT20 KRT7
35	dermoid cyst	10.6	KRT20 KRT7
36	large cell acanthoma	10.6	KRT7 MTOR
37	immune system organ benign neoplasm	10.6	KRT20 KRT7
38	thymus lipoma	10.6	KRT20 KRT7
39	cystadenofibroma	10.6	KRT20 KRT7
40	ovarian mucinous neoplasm	10.6	KRT20 KRT7
41	cystic teratoma	10.6	KRT20 KRT7
42	horseshoe kidney	10.6	KRT20 KRT7
43	inverted papilloma	10.6	KRT20 KRT7
44	adenocarcinoma in situ	10.6	KRT20 KRT7
45	ovarian cystic teratoma	10.6	KRT20 KRT7
46	morpheaform basal cell carcinoma	10.6	CDH1 KRT20
47	pancreatic mucinous cystadenoma	10.6	KRT20 KRT7
48	kidney benign neoplasm	10.6	KRT7 MTOR
49	large cell neuroendocrine carcinoma	10.6	KRT20 KRT7
50	renal pelvis adenocarcinoma	10.6	CDH1 KRT7

Graphical network of the top 20 diseases related to Large Intestine Adenocarcinoma:

Sources

Symptoms & Phenotypes for Large Intestine Adenocarcinoma

GenomeRNAi Phenotypes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.02	CDH1 EIF4EBP1 KRT7 MCM3 MTOR

MGI Mouse Phenotypes related to Large Intestine Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.17	CDH1 CTNNB1 EIF4EBP1 KRT7 MCM3 MTOR

Sources

Drugs & Therapeutics for Large Intestine Adenocarcinoma

Drugs for Large Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved

Phase 4

7439-89-6

23925

Ferric Compounds

Phase 4

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Hepcidins

Phase 4

Iron Supplement

Nutraceutical

Phase 4

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

61825-94-3

5310940 9887054 43805 6857599

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

51-21-8

3385

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1

68538-85-2

Irinotecan

Approved, Investigational

Phase 2, Phase 3,Phase 1

97682-44-5, 100286-90-6

60838

Nicotine

Approved

Phase 3

54-11-5

942 89594

leucovorin

Approved, Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

143 6006

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-30-3

6037

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Antidotes

Phase 3,Phase 2,Phase 1,Not Applicable

Calcium, Dietary

Phase 3,Phase 2

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Protective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2

Antibodies

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Micronutrients

Phase 3,Phase 2,Phase 1,Not Applicable

Trace Elements

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B Complex

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamins

Phase 3,Phase 2,Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 3,Phase 2

Endothelial Growth Factors

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2,Phase 1

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Mitomycins

Phase 2, Phase 3

Folate

Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B9

Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Everolimus

Approved

Phase 2,Phase 1

159351-69-6

6442177

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2,Phase 1

53123-88-9

5284616 6436030 46835353

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Cetuximab

Approved

Phase 2,Phase 1

205923-56-4

56842117 2333

Tegafur

Approved, Investigational

Phase 2

17902-23-7

5386

Azacitidine

Approved, Investigational

Phase 1, Phase 2

320-67-2

9444

Interventional clinical trials:

(show top 50) (show all 119)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Iron: Measuring Response in Anemic Surgical Patients	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia	Completed	NCT01701310	Phase 4	Ferric carboxymaltose;Ferrous Sulphate
3	Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases	Completed	NCT00265356	Phase 3
4	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
5	Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM	Recruiting	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
6	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
7	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Recruiting	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
8	Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases.	Recruiting	NCT02758951	Phase 2, Phase 3	Perioperative systemic therapy
9	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Active, not recruiting	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
10	Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）	Active, not recruiting	NCT02390947	Phase 3	Famitinib;Placebo
11	Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
12	Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .	Unknown status	NCT02788006	Phase 2	Regorafenib 160 mg
13	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
14	Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma	Unknown status	NCT00075556	Phase 2	capecitabine
15	Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
16	Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	Unknown status	NCT00104689	Phase 2	capecitabine;oxaliplatin
17	Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
18	Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
19	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20	Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
21	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
22	Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
23	Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma	Completed	NCT01479465	Phase 2	Simtuzumab;FOLFIRI;Placebo to match simtuzumab
24	DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT00080834	Phase 2	DJ-927
25	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
26	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
27	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
28	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Completed	NCT01730586	Phase 2	Abraxane
29	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib	Completed	NCT00582660	Phase 2	Celecoxib;Placebo
30	Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer	Completed	NCT00003220	Phase 2	bryostatin 1
31	Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer	Completed	NCT00025350	Phase 2	gefitinib
32	Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone	Completed	NCT00890305	Phase 2	CT-011;FOLFOX
33	Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	Completed	NCT00149396	Phase 1, Phase 2	NV1020
34	1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer	Completed	NCT01417494	Phase 2	Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
35	Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer	Completed	NCT00123851	Phase 2	Tarceva (OSI-774);Capecitabine;Oxaliplatin
36	Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy	Completed	NCT01225744	Phase 2	Cetuximab;Irinotecan;Oxaliplatin;UFT
37	Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed	Completed	NCT00259844	Phase 2
38	Azacitidine and CAPOX in Metastatic Colorectal Cancer	Completed	NCT01193517	Phase 1, Phase 2	Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
39	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	Recruiting	NCT02185443	Phase 2
40	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Recruiting	NCT03069950	Phase 2	Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
41	Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)	Recruiting	NCT02738606	Phase 2	Chemotherapy
42	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Recruiting	NCT03442569	Phase 2	Panitumumab;Nivolumab;Ipilimumab
43	Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer	Recruiting	NCT01053013	Phase 2
44	A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Recruiting	NCT02599324	Phase 1, Phase 2	ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab
45	Regorafenib in Metastatic Colorectal Cancer	Recruiting	NCT02466009	Phase 2	Regorafenib
46	Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors	Recruiting	NCT01876511	Phase 2	MK-3475;MK-3475
47	A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer	Recruiting	NCT03206073	Phase 1, Phase 2
48	TAS102 in Combination With NAL-IRI in Advanced GI Cancers	Recruiting	NCT03368963	Phase 1, Phase 2	Nanoliposomal Irinotecan;Trifluridine and Tipiracil Hydrochloride
49	Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer	Recruiting	NCT03043313	Phase 2	Tucatinib
50	Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer	Recruiting	NCT03087071	Phase 2	Panitumumab;Trametinib

Search NIH Clinical Center for Large Intestine Adenocarcinoma

Sources

Genetic Tests for Large Intestine Adenocarcinoma

Sources

Anatomical Context for Large Intestine Adenocarcinoma

MalaCards organs/tissues related to Large Intestine Adenocarcinoma:

⁴¹

Liver, Colon, Lung, Endothelial, Kidney, Bone

Sources

Publications for Large Intestine Adenocarcinoma

Articles related to Large Intestine Adenocarcinoma:

#	Title	Authors	Year
1	Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. ( 12647790 )	Dziegiel P....Zabel M.	2003

Sources

Genes for Large Intestine Adenocarcinoma

Genes related to Large Intestine Adenocarcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KRT20	Keratin 20	Protein Coding	15.72	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	KRT7	Keratin 7	Protein Coding	14.19	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	13.68	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	CDH1	Cadherin 1	Protein Coding	13.43	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	CTNNB1	Catenin Beta 1	Protein Coding	13.28	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	MCM3	Minichromosome Maintenance Complex Component 3	Protein Coding	6.08	DISEASES inferred ¹⁵
7	PIP	Prolactin Induced Protein	Protein Coding	5.13	DISEASES inferred ¹⁵
8	EIF4EBP1	Eukaryotic Translation Initiation Factor 4E Binding Protein 1	Protein Coding	4.8	DISEASES inferred ¹⁵

Sources

Variations for Large Intestine Adenocarcinoma

Sources

Expression for Large Intestine Adenocarcinoma

Search GEO for disease gene expression data for Large Intestine Adenocarcinoma.

Sources

Pathways for Large Intestine Adenocarcinoma

Pathways related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.48	CDH1 CTNNB1 EIF4EBP1 MTOR
2	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.26	CDH1 CTNNB1 MTOR
3	Cytoskeletal Signaling ⁴	12.25	CDH1 KRT20 KRT7
4	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	11.84	CDH1 CTNNB1 MTOR
5	Integrated Breast Cancer Pathway ¹	11.69	CDH1 CTNNB1 MTOR
6	UVA-Induced MAPK Signaling ⁶⁴ Show member pathways UVB-Induced MAPK Signaling ⁶⁴	11.68	EIF4EBP1 MTOR
7	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.6	CTNNB1 EIF4EBP1 MTOR
8	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	11.55	CDH1 CTNNB1 EIF4EBP1 MTOR
9	Brain-Derived Neurotrophic Factor (BDNF) signaling pathway ¹	11.49	CTNNB1 EIF4EBP1 MTOR
10	Interferon type I signaling pathways ¹	11.35	EIF4EBP1 MTOR
11	Wnt Signaling Pathway Netpath ¹	11.33	CTNNB1 MTOR
12	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.25	EIF4EBP1 MTOR
13	Arf6 trafficking events ¹	11.21	CDH1 CTNNB1
14	Cell adhesion_Cadherin-mediated cell adhesion ²²	11.16	CDH1 CTNNB1
15	Stabilization and expansion of the E-cadherin adherens junction ¹	11.15	CDH1 CTNNB1
16	BDNF-TrkB Signaling ¹	11.07	EIF4EBP1 MTOR
17	E-cadherin signaling in the nascent adherens junction ¹	11.04	CDH1 CTNNB1
18	Extracellular vesicle-mediated signaling in recipient cells ¹	10.99	CTNNB1 MTOR
19	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ¹	10.97	EIF4EBP1 MTOR
20	Follicle Stimulating Hormone (FSH) signaling pathway ¹	10.91	EIF4EBP1 MTOR
21	Nectin adhesion pathway ¹	10.85	CDH1 CTNNB1
22	4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression ¹	10.66	EIF4EBP1 MTOR
23	RHO GTPases activate IQGAPs ⁶⁶	10.07	CDH1 CTNNB1

Sources

GO Terms for Large Intestine Adenocarcinoma

Cellular components related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	catenin complex	GO:0016342	9.16	CDH1 CTNNB1
2	apical junction complex	GO:0043296	8.96	CDH1 CTNNB1
3	flotillin complex	GO:0016600	8.62	CDH1 CTNNB1

Biological processes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.4	CTNNB1 MTOR
2	adherens junction organization	GO:0034332	9.37	CDH1 CTNNB1
3	TOR signaling	GO:0031929	9.32	EIF4EBP1 MTOR
4	regulation of osteoclast differentiation	GO:0045670	9.26	CTNNB1 MTOR
5	regulation of myelination	GO:0031641	9.16	CTNNB1 MTOR
6	entry of bacterium into host cell	GO:0035635	8.96	CDH1 CTNNB1
7	cellular response to indole-3-methanol	GO:0071681	8.62	CDH1 CTNNB1

Sources

Sources for Large Intestine Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia